• Explore /
  • Poster
  • / Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC).

Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC).

Abstract Poster

Authors

Nong Xu

Nong Xu

The First Affiliated Hospital, Zhejiang University, Hangzhou, China

Nong Xu , Lin Shen , Haiping Jiang , Yulong Zheng , Jiong Qian , Chenyu Mao , Hui Zhou , Shuyan Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02937116

Citation

J Clin Oncol 37, 2019 (suppl; abstr 4042)

DOI

10.1200/JCO.2019.37.15_suppl.4042

Abstract #

4042

Poster Bd #

147

Abstract Disclosures

Similar Posters

First Author: Chenyu Mao

First Author: Deirdre Jill Cohen

First Author: Jin Yan

First Author: John Ebben